RECURRENT MANTLE CELL LYMPHOMA

This early-stage trial tests the safety and best dose of two drugs, ibrutinib and palbociclib, given together to people with mantle cell lymphoma that has come back after prior treatment. The drugs work by blocking enzymes that cancer cells need to grow. About 28 adults with meas…

This early-phase study tests a combination of two drugs, ibrutinib and lenalidomide, in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The main goals are to find the safest dose and understand side effects. About 39 participan…

This study tests a combination of two drugs—nivolumab and lenalidomide—in people with non-Hodgkin or Hodgkin lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see how well the drugs work together. About 36 adults with specific …

This early-phase study tests a combination of three drugs (alisertib, bortezomib, and rituximab) in adults with mantle cell or low-grade non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and check for side effects…

This early-stage study tests a combination of two drugs, copanlisib and venetoclax, in adults with mantle cell lymphoma that has come back or no longer responds to standard treatments. The goal is to find the safest dose and see how well the drugs work together to shrink or contr…

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study tests a combination of two drugs, ibrutinib and rituximab, in people with mantle cell lymphoma that has come back or not responded to treatment, or in older adults newly diagnosed with the disease. The goal is to shrink tumors and control the cancer. About 113 particip…

This study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…

This early-phase study tests a new treatment for adults with B-cell cancers (like lymphoma or leukemia) that returned after prior therapy. Doctors take a patient's own white blood cells, add a gene to help them find and kill cancer cells, and give them back after chemotherapy. Th…

This early-phase study tests a new type of immunotherapy for people with high-risk B-cell non-Hodgkin lymphoma that has come back after initial treatment. Participants first receive a stem cell transplant, then get an infusion of their own immune cells that have been genetically …

This early-stage trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogn…

This study tests adding an experimental drug called selinexor to the standard chemotherapy R-CHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced …

This study tests a combination of two targeted drugs, venetoclax and acalabrutinib, in 32 patients with mantle cell lymphoma that either returned after treatment or never fully responded. The goal is to see how many patients achieve a complete response, meaning no signs of cancer…

This early-phase trial tests the safety and best dose of specially modified T-cells (immune cells) given after a stem cell transplant for people with high-risk or returning non-Hodgkin lymphoma. The modified T-cells are designed to recognize and attack cancer cells. The study inv…

This early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …

This early-phase trial tests a new approach for people with aggressive B-cell non-Hodgkin lymphoma that has come back after treatment. After a standard stem cell transplant, patients receive their own immune cells (T cells) that have been genetically modified in a lab to better r…

This early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…